Cart
0

Cancer Tumor Profiling Market by Technology [Next-generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), (Fluorescence In Situ Hybridization (FISH) and Chromogenic in Situ Hybridization (CISH)), Microarray, and Others], Technique (Genomics, Proteomics, Epigenetics, and Metabolomics), and Application (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, and Research Applications) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Get 20% Free Customization In This Report
LI_172717
Pages: 190
Aug 2017 | 2511 Views
 
Author's : Tanvi Sapatnekar & Garima Chandra
Tables: 57
Charts: 61
 

Cancer/Tumor Profiling Market

Global Cancer/tumor Profiling Market was valued at $25,318 million in 2016, and is expected to reach $82,447 million by 2023, registering a CAGR of 18.4% from 2017 to 2023. Cancer/tumor profiling provides information about the genes causing cancer, which would offer useful insights related to the mechanism of cancer. The potential of cancer profiling is not only limited to common cancers, such as lymphoma and breast cancer, but also is useful in molecular profiling of lung cancer, prostate cancer, and acute leukemia. Cancer profiling has plays a vital role in diagnosis at the molecular level, as better understanding of the cancer tumors helps physicians to make appropriate therapeutic decisions and avoid “over-treatment” of the cancer patients.

The global market is driven by growing demand for cancer profiling method by oncologists to diagnose or treat cancers as well as predict response to targeted therapy. In addition, rise in adoption of cancer biomarkers for tumor profiling, increase in incidence of cancer across the globe, and growth in use of next-generation sequencing technique for cancer profiling boost the market growth. However, high monetary investments for the development of biomarkers and dearth of skilled professionals or oncologists specific to tumor profiling hamper the market growth.

Global Cancer/Tumor Profiling Market Segmentation

Global Cancer/Tumor Profiling Market Segmentation

Get more information on this report : Request Sample Pages

Drivers, Restraints, and Opportunities

The impact of the driving factors is expected to surpass that of restraints. Moreover, increase in focus towards personalized medicine offer lucrative opportunities for the market growth.

Global Cancer/Tumor Profiling Market: Drivers, and Restraints,

Global Cancer/Tumor Profiling Market: Drivers, and Restraints

Get more information on this report : Request Sample Pages

Segment Review

The global cancer/tumor profiling market is segmented based on technology, technique, application, and region. Based on technology, it is classified into next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), microarray, and others. The in-situ hybridization segment is further categorized into fluorescence in situ hybridization (FISH) and chromogenic in situ hybridization (CISH). Based on technique, the market is classified into genomics, proteomics, epigenetics, and metabolomics. Based on application, it is divided into personalized medicine, diagnostics, biomarker discovery, prognostics, and research applications. The cancer/tumor profiling market is analyzed across four regions namely, North America, Europe, Asia-Pacific, and LAMEA.

China Cancer/Tumor Profiling Market, 2016-2023 ($Million)

China Cancer/Tumor Profiling Market, 2016-2023 ($Million)

Get more information on this report : Request Sample Pages

China offers lucrative opportunities for the market growth, owing to significant development of precision medicine in the region. In addition, advanced cancer testing in this country is associated with its research prowess in genome sequencing and large patient base in urban areas.

The report provides a comprehensive analysis of the key players operating in the global market, which include Qiagen N.V., Roche Molecular Systems Inc., Abott Molecular, Illumina Inc., NeoGenomics Laboratories, HTG Molecular Diagnostic, Genomic Health Inc., Hologic Gen-Probe, BD Biosciences, and Siemens Healthineers.

The other key players in the value chain include Claris Life Sciences, Personal Genome Diagnostics, Inc., Perthera, Inc., Foundation Medicine, Inc. V., Strand, ApoCell, Contextual Genomics, Agendia, and GenScript.

Key Benefits

  • The study provides an in-depth analysis along with the current trends and future estimations of the global cancer/tumor profiling market to elucidate the imminent investment pockets.
  • Comprehensive analyses of the factors that drive and restrict the market growth are provided in the report.
  • The quantitative analysis of the industry for the period of 2016 to 2023 is provided to enable stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of key segments of the industry is provided to understand the type of techniques and methods used across the globe.
  • Key market players and their strategies are analyzed to understand the competitive outlook of the market.

Cancer/Tumor Profiling Market Key Segments:

By Technology

  • Next-generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • In Situ Hybridization (ISH)
    • Fluorescence In Situ Hybridization (FISH)
    • Chromogenic In Situ Hybridization (CISH)
  • Microarray
  • Others

By Technique

  • Genomics
  • Proteomics
  • Epigenetics
  • Metabolomics

By Application

  • Personalized Medicine
  • Diagnostics
  • Biomarker Discovery
  • Prognostics
  • Research Applications

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • France
    • Germany
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Turkey
    • Argentina
    • South Africa
    • Rest of LAMEA
 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1 CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTERS FIVE FORCES ANALYSIS
3.4. REGULATORY FRAMEWORK
3.5. MARKET SHARE ANALYSIS, 2016
3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Rise in the adoption of the cancer profiling methods by oncologists
3.6.1.2. Increase in the use of biomarkers in cancer profiling
3.6.1.3. Increase in the demand for next-generation sequencing technique in cancer profiling
3.6.1.4. Rise in incidence of cancer across the globe

3.6.2. Restraints

3.6.2.1. High monetary investments in the development of biomarkers
3.6.2.2. Dearth of skilled professionals

3.6.3. Opportunities

3.6.3.1. Increasing demand for personalized medicine

Chapter: 4 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. NEXT-GENERATION SEQUENCING (NGS)

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. POLYMERASE CHAIN REACTION (PCR)

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. IMMUNOHISTOCHEMISTRY (IHC)

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. IN SITU HYBRIDIZATION (ISH)

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast
4.5.1. Fluorescence in Situ Hybridization (FISH)

4.5.1.1. Market Size & Forecast

4.5.2. Chromogenic in Situ Hybridization (CISH)

4.5.2.1. Market Size & Forecast

4.6. MICROARRAY

4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast

4.7. OTHER TECHNOLOGIES

4.7.1. Key market trends
4.7.2. Growth factors and opportunities
4.7.3. Market size and forecast

Chapter: 5 CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. GENOMICS

5.2.1. Market size and forecast

5.3. PROTEOMICS

5.3.1. Market size and forecast

5.4. EPIGENETICS

5.4.1. Market size and forecast

5.5. METABOLOMICS

5.5.1. Market size and forecast

Chapter: 6 CANCER/TUMOR PROFILING MARKET, BY APPLICATION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. PERSONALIZED MEDICINE

6.2.1. Market size and forecast

6.3. DIAGNOSTICS

6.3.1. Market size and forecast

6.4. BIOMARKER DISCOVERY

6.4.1. Market size and forecast

6.5. PROGNOSTICS

6.5.1. Market size and forecast

6.6. RESEARCH APPLICATIONS

6.6.1. Market size and forecast

Chapter: 7 CANCER/TUMOR PROFILING MARKET, BY GEOGRAPHY

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast

7.2.3.1. U.S. market size and forecast
7.2.3.2. Mexico market size and forecast
7.2.3.3. Canada market size and forecast

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast

7.3.3.1. UK market size and forecast
7.3.3.2. France market size and forecast
7.3.3.3. Germany market size and forecast
7.3.3.4. Italy market size and forecast
7.3.3.5. Spain market size and forecast
7.3.3.6. Rest of Europe market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast

7.4.3.1. Japan market size and forecast
7.4.3.2. China market size and forecast
7.4.3.3. India market size and forecast
7.4.3.4. Australia market size and forecast
7.4.3.5. Rest of Asia-Pacific market size and forecast

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast

7.5.3.1. Brazil market size and forecast
7.5.3.2. Argentina market size and forecast
7.5.3.3. Turkey market size and forecast
7.5.3.4. South Africa market size and forecast
7.5.3.5. Rest of LAMEA market size and forecast

Chapter: 8 COMPANY PROFILES

8.1. QIAGEN N.V.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Business performance
8.1.5. Key strategic moves and developments

8.2. ROCHE MOLECULAR SYSTEMS INC.

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Business performance
8.2.5. Key strategic moves and developments

8.3. ABBOTT LABORATORIES

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Business performance
8.3.5. Key strategic moves and developments

8.4. ILLUMINA INC.

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Business performance
8.4.5. Key strategic moves and developments

8.5. NEOGENOMICS LABORATORIES

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance
8.5.5. Key strategic moves and developments

8.6. HTG MOLECULAR DIAGNOSTIC

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Business performance
8.6.5. Key strategic moves and developments

8.7. GENOMIC HEALTH INC.

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Business performance
8.7.5. Key strategic moves and developments

8.8. HOLOGIC GEN-PROBE

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Business performance
8.8.5. Key strategic moves and developments

8.9. BD BIOSCIENCES (BECKTON DICKINSON)

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Business performance
8.9.5. Key strategic moves and developments

8.10. SIEMENS HEALTHINEERS

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Business performance
8.10.5. Key strategic moves and developments

LIST OF TABLES

TABLE 1. GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 2. GLOBAL CANCER/TUMOR PROFILING MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2016-2023 ($MILLION)
TABLE 3. GLOBAL CANCER/TUMOR PROFILING MARKET FOR POLYMERASE CHAIN REACTION (PCR), BY REGION, 2016-2023 ($MILLION)
TABLE 4. GLOBAL CANCER/TUMOR PROFILING MARKET FOR IMMUNOHISTOCHEMISTRY (IHC), BY REGION, 2016-2023 ($MILLION)
TABLE 5. GLOBAL CANCER/TUMOR PROFILING MARKET FOR IN SITU HYBRIDIZATION (ISH), BY REGION, 2016-2023 ($MILLION)
TABLE 6. GLOBAL CANCER/TUMOR PROFILING MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2016-2023 ($MILLION)
TABLE 7. GLOBAL CANCER/TUMOR PROFILING MARKET FOR CHROMOGENIC IN SITU HYBRIDIZATION (CISH), BY REGION, 2016-2023 ($MILLION)
TABLE 8. GLOBAL CANCER/TUMOR PROFILING MARKET FOR MICROARRAY, BY REGION, 2016-2023 ($MILLION)
TABLE 9. GLOBAL CANCER/TUMOR PROFILING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2016-2023 ($MILLION)
TABLE 10. GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 11. GLOBAL CANCER/TUMOR PROFILING MARKET FOR GENOMICS, BY REGION, 2016-2023 ($MILLION)
TABLE 12. GLOBAL CANCER/TUMOR PROFILING MARKET FOR PROTEOMICS, BY REGION, 2016-2023 ($MILLION)
TABLE 13. GLOBAL CANCER/TUMOR PROFILING MARKET FOR EPIGENETICS, BY REGION, 2016-2023 ($MILLION)
TABLE 14. GLOBAL CANCER/TUMOR PROFILING MARKET FOR METABOLOMICS, BY REGION, 2016-2023 ($MILLION)
TABLE 15. GLOBAL CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 16. GLOBAL CANCER/TUMOR PROFILING MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2016-2023 ($MILLION)
TABLE 17. GLOBAL CANCER/TUMOR PROFILING MARKET FOR DIAGNOSTICS, BY REGION, 2016-2023 ($MILLION)
TABLE 18. GLOBAL CANCER/TUMOR PROFILING MARKET FOR BIOMARKER DISCOVERY, BY REGION, 2016-2023 ($MILLION)
TABLE 19. GLOBAL CANCER/TUMOR PROFILING MARKET FOR PROGNOSTICS, BY REGION, 2016-2023 ($MILLION)
TABLE 20. GLOBAL CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2016-2023 ($MILLION)
TABLE 21. GLOBAL CANCER/TUMOR PROFILING MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 22. NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 23. NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 24. NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE. NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 26. EUROPE CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 27. EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 28. EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 29. EUROPE CANCER VACCINES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 30. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 31. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 32. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 33. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 34. LAMEA CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 35. LAMEA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 36. LAMEA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 37. LAMEA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 38. QIAGEN: COMPANY SNAPSHOT
TABLE 39. QIAGEN: OPERATING SEGMENTS
TABLE 40. ROCHE: COMPANY SNAPSHOT
TABLE 41. ROCHE: OPERATING SEGMENTS
TABLE 42. ABBOTT: COMPANY SNAPSHOT
TABLE 43. ABBOTT: OPERATING SEGMENTS
TABLE 44. ILLUMINA: COMPANY SNAPSHOT
TABLE 45. ILLUMINA: OPERATING SEGMENTS
TABLE 46. NEOGENOMICS: COMPANY SNAPSHOT
TABLE 47. ADURO: OPERATING SEGMENTS
TABLE 48. HTG: COMPANY SNAPSHOT
TABLE 49. HTG: OPERATING SEGMENTS
TABLE 50. GENOMIC HEALTH: COMPANY SNAPSHOT
TABLE 51. GENOMIC HEALTH: OPERATING SEGMENTS
TABLE 52. HOLOGIC: COMPANY SNAPSHOT
TABLE 53. HOLOGIC: OPERATING SEGMENTS
TABLE 54. BD: COMPANY SNAPSHOT
TABLE 55. BD: OPERATING SEGMENTS
TABLE 56. SIEMENS: COMPANY SNAPSHOT
TABLE 57. SIEMENS: OPERATING SEGMENTS

LIST OF FIGURES

FIGURE 1. GLOBAL CANCER/TUMOR PROFILING MARKET, 2016-2023
FIGURE 2. SEGMENTATION OF CANCER/TUMOR PROFILING MARKET
FIGURE 3. TOP INVESTMENT POCKETS IN GLOBAL CANCER/TUMOR PROFILING MARKET
FIGURE 4. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)
FIGURE 5. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 6. TOP WINNING STRATEGIES: NATURE AND COMPANY
FIGURE 7. BARGAINING POWER OF BUYERS
FIGURE 8. BARGAINING POWER OF SUPPLIERS
FIGURE 9. THREAT OF NEW ENTRANTS
FIGURE 10. THREAT OF SUBSTITUTION
FIGURE 11. COMPETITIVE RIVALRY
FIGURE 12. RESTRAINTS AND DRIVERS: GLOBAL CANCER/TUMOR PROFILING MARKET
FIGURE 13. U.S. CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 14. MEXICO CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 15. CANADA CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 16. UK CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 17. FRANCE CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 18. GERMANY CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 19. ITALY CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 20. SPAIN CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 21. REST OF EUROPE CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 22. JAPAN CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 23. CHINA CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 24. INDIA CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE. AUSTRALIA CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 26. REST OF ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 27. BRAZIL CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 28. ARGENTINA CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 29. TURKEY CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 30. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 31. REST OF LAMEA CANCER/TUMOR PROFILING MARKET, 2016-2023 ($MILLION)
FIGURE 32. QIAGEN: NET SALES, 2014-2016 ($MILLION)
FIGURE 33. QIAGEN: REVENUE BY SEGMENT, 2016 (%)
FIGURE 34. QIAGEN: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 35. ROCHE: NET SALES, 2014-2016 ($MILLION)
FIGURE 36. ROCHE: REVENUE BY SEGMENT, 2016 (%)
FIGURE 37. ROCHE: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 38. ABBOTT: NET SALES, 2014-2016 ($MILLION)
FIGURE 39. ABBOTT: REVENUE BY SEGMENT, 2016 (%)
FIGURE 40. ABBOTT: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 41. ILLUMINA: NET SALES, 2014-2016 ($MILLION)
FIGURE 42. ILLUMINA: REVENUE BY SEGMENT, 2016 (%)
FIGURE 43. ILLUMINA: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 44. NEOGENOMICS: NET SALES, 2014-2016 ($MILLION)
FIGURE 45.NEOGENOMICS: REVENUE BY SEGMENT, 2016 (%)
FIGURE 46. NEOGENOMICS: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 47. HTG: NET SALES, 2014-2016 ($MILLION)
FIGURE 48. HTG: REVENUE BY SEGMENT, 2016 (%)
FIGURE 49. HTG: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 50. GENOMIC HEALTH: NET SALES, 2014-2016 ($MILLION)
FIGURE 51. GENOMIC HEALTH: REVENUE BY SEGMENT, 2016 (%)
FIGURE 52. GENOMIC HEALTH: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 53. HOLOGIC: NET SALES, 2014-2016 ($MILLION)
FIGURE 54. HOLOGIC: REVENUE BY SEGMENT, 2016 (%)
FIGURE 55. HOLOGIC: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 56. BD: NET SALES, 2014-2016 ($MILLION)
FIGURE 57. BD: REVENUE BY SEGMENT, 2016 (%)
FIGURE 58. BD: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 59. SIEMENS: NET SALES, 2014-2016 ($MILLION)
FIGURE 60. SIEMENS: REVENUE BY SEGMENT, 2016 (%)
FIGURE 61. SIEMENS: REVENUE BY GEOGRAPHY, 2016 (%)

 

Cancer/tumor profiling enables extensive analysis of tumor and study of the genetic characteristics. It has gained importance over the years, as cancer profiling methodologies provide useful information related to cancer tumor. The information obtained through cancer profiling is utilized in designing an appropriate therapeutic treatment for any individual suffering from cancer. Rise in incidence of cancer across the globe has fueled the demand for molecular profiling techniques for cancer identification. In addition, increase in awareness related to different types of cancers, such as breast cancer, oral, and pancreatic, among others supplement the market growth. Oncologists use cancer profiling methods to differentiate between cancer cells at the molecular level.

Cancer profiling is performed through various methods such as, next-generation sequencing (NGS), polymerase chain reaction (PCR), in situ Hybridization (ISH), immunohistochemistry (IHC), microarray, and others. The next-generation sequencing (NGS) segment has a major share in the global market, and oncologists showcase high adoption of NGS technologies for cancer profiling. NGS enables a deep sequencing of tumor biopsies, fine needle aspirations (FNAs), or circulating tumor cells (CTCs). This enables a detailed profiling of cancer through the identification of mutations, thereby boosting the demand for NGS. However, fluorescence in situ hybridization has gained traction in the recent years due to higher sensitivity than NGS. The personalized medicine segment is anticipated to drive the global market, and the routine use of customized profiling panels including FISH as well as NGS is set to increase in near future.

The techniques involved in cancer profiling include genomics, proteomics, epigenetics, and metabolomics. Proteomics is the second most popular technique used in the cancer profiling market, as the quantitative assessment of protein levels in malignant tumors through proteomics profiling techniques plays a major role in comprehensive understanding of cancer. This protein quantitative assessment is crucial to ensure accurate diagnosis as well as to provide therapy to the cancer patients. Rise in incidence of breast cancers across the globe and increase in focus towards targeted therapy for cancer patients are expected to boost the market growth in the near future.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request Sample

Request Customization

Request sample

OR

Purchase Full Report of
Cancer Tumor Profiling Market- Global Opportunity Analysis and Industry Forecast, 2017-2023

  • Online Only
  • $3456
  • Online cloud Access only
  • Restricted Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $3840
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5370
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6450
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $8995
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo